Verge Genomics - Tech Innovator Profile
Summary
Founded in 2015, Verge Genomics is an AI-driven biopharmaceutical drug discovery company that applies patient genomes, epigenomics, and gene expression for identifying novel effective drugs; stratify patient subpopulations, and therapeutic gene targets for accelerating clinical success. Verge Genomics is focusing on three neurodegenerative diseases: frontotemporal dementia (FTD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS).
Scope
The report provides information and insights into Verge Genomics, including -
- Overview of the company and its product offering
- Detailed insight into its business model, company type and headquarter
- Information on funding and partnership
- Biography of top management
- Gain insights into Verge Genomics' business operations.
- Gain insights into partnership and funding.
- Gain understanding about its technology focus.
Loading...
In this report,
Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).
Please note that your term must be at least three characters long and numbers will be blocked by the # sign.
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook